生脉散治疗慢性心力衰竭的临床应用现状  

Current status of clinical application of Shengmaisan in the treatment of chronic heart

作　　者：耿新冉 杨硕[2] GENG Xin-ran;YANG Shuo(Fourth Clinical College,Liaoning Universiyty of Traditional Chinese Medicine,Shenyang 110847,Liaoning Province,China;Departmentof Cardiovascular Medicine,The Fourth Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Shenyang 110847,Liaoning Province,China)

机构地区：[1]辽宁中医药大学第四临床学院,辽宁沈阳110847 [2]辽宁中医药大学附属第四医院心血管内科,辽宁沈阳110847

出　　处：《中国临床药理学杂志》2024年第22期3328-3332,共5页The Chinese Journal of Clinical Pharmacology

基　　金：全国名老中医药专家传承工作室建设基金项目(国中医药人教发[2022]75号);中国中医药研究促进会基金资助项目(中医促会[2022]109号);辽宁省中医大师传承工作室基金资助项目(辽中医药发[2022]1号);辽宁省中医药临床专科建设基金资助项目(辽财指社[2016]38号)。

摘　　要：慢性心力衰竭(CHF)有较高的发病率和死亡率,中医运用生脉散在治疗CHF方面具有独特的优势。生脉散可以改善心力衰竭患者的临床症状,提高生活质量,其主要通过抑制神经内分泌系统、抑制免疫炎症反应、抑制心肌纤维化、抑制心肌细胞凋亡、抗氧化应激反应、降低Ca^(2+)泄露增加心肌收缩力等多种途径来发挥作用。本文对近年来生脉散治疗CHF进行论述,以期能更好地应用于临床。Chronic heart failure(CHF)has high morbidity and mortality.The application of Shengmaisan in traditional Chinese medical science has unique advantage in the treatment of chronic heart failure.Shengmaisan can improve the clinical symptoms and quality of life of patients with heart failure.It mainly plays its role through inhibition of neuroendocrine system,inhibition of immune inflammation response,inhibition of myocardial fibrosis,inhibition of cardiomyocyte apoptosis,anti-oxidative stress response,reduced Ca^(2+)leakage and increase myocardial contractility.This article discusses the treatment of chronic heart failure with Shengmaisan in recent years,in order to better clinical application.

关 键 词：生脉散 慢性心力衰竭 临床应用 作用机制 

分 类 号：R28[医药卫生—中药学]